SEC Form 4 · accession 0001225208-15-010603
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce N Kuhlik
Officer — Exe V-P & Gen Counsel
Period of report
Apr 29, 2015
Accepted (ET)
Apr 29, 2015 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 29, 2015 | M | 112,126 | $39.29 | A | 256,921 | D | |
| Common Stock | Apr 29, 2015 | M | 44,776 | $36.56 | A | 301,697 | D | |
| Common StockF1 | Apr 29, 2015 | S | 65,306 | $59.5793 | D | 236,391 | D | |
| Common StockF2,F3 | Apr 29, 2015 | S | 91,596 | $60.00 | D | 144,795 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $39.29 | Apr 29, 2015 | M | 112,126 | D | May 2, 2013 | May 1, 2022 | Common Stock | 112,126 | 56,064 | D |
| Stock Option (right to buy)F5 | $36.56 | Apr 29, 2015 | M | 44,776 | D | May 4, 2012 | May 3, 2021 | Common Stock | 44,776 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.2600 to $59.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.8600 to $60.4100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F3Holdings include shares acquired in dividend reinvestment transactions.
- F4The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
- F5The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014.